Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Focus
REGN logo

Regeneron Nets $1.46B Income Up 13% in Q3 Despite EYLEA Biosimilar Hit

REGN10-QFiling Date: 10/28/2025
Regeneron Pharmaceuticals, Inc.
Description

What this story covers

Regeneron reports Q3 2025 revenues of $3.75B, up slightly, with net income rising 13% to $1.46B amid EYLEA sales decline from biosimilars. Collaboration revenue grows via Dupixent; robust balance sheet supports R&D and buybacks. Pipeline advances offset risks like regulatory delays and competition.

Story snapshot

CompanyRegeneron Pharmaceuticals, Inc.
TickerREGN
VariantStandard detailed
Duration9:25
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000872589-25-000028

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in